Marc Laniado MD FEBU FRCS(Urol)!Consultant Urologist

Prostate Cancer and BPHManagement Revolutionised

2

Prostate cancer is common and causes death worldwide

BPH incidence by AgeProstate Cancer

3

Conventional diagnosis is haphazard& treatments have side-effects

4

Adopt innovations in imaging& treatment technology

Multparametric MRIto show cancer

Focal Treatment totreat target + margin

Urolift treat BPHretain quality of life

5

The OLD PATHWAY to get tissue

6

Transrectal prostate biopsies to sample prostate

ProstateRectum Ultrasound

Probe

significant infection in 1 to 4% of men

7

Transrectal biopsies miss cancerat the front of the prostate

CANCER

PROSTATE

Front

Back

1 Underdiagnosis

Transrectal biopsy needles passing from rectum into prostate

8

On unguided biopsies, a direct hit of asmall cancer may be over-interpreted

CANCER

Front

Back

1 Underdiagnosis!

Transrectal biopsy needles passing from rectum into prostate

2 Overdiagnosis

9

Traditional diagnostic pathway hasmultiple problems

Overemphasis men withinflammation or big prostates

Misses men with cancer insmall prostates

Prostate examination is unreliable

“Transfaecal" biopsy Unguided & misses abnormalities

May have found aninsignificant cancer

May save lives butcould overtreat

‘False negative’

Still has cancer!

10

Active surveillance fails in1/3 men because high-riskdisease not recognised at diagnosis on TRUS biopsy

64% at 10 years no treatment

Klotz  2015  JCO

11

The cool new pathway…

12

Multiparametric MRI showsthe location of prostate cancer

13

Enhanced mpMRIcan “see”prostate cancerthat cannot be felt

The same part of the prostate examined by MRI in differentways (“multiparametric MRI”) exposes cancer

14

Having identified potential canceron MRI, target the biopsy to it

Transperineal biopsies can reach the front of the prostate

15

Transperineal biopsies reachfront & back of prostate

16

By fusing the USS and MRI images, the biopsyneedle is guided into exactly the correct place

17

mpMRI-targeted prostate biopsies:↑30% high grade & ↓20% low grade

•  Biopsy naive and previous negative biopsies•  MRTB v 12-core biopsies•  33% v 24% high grade cancer•  30% more high risk,•  17% fewer low risk•  If add 12 core systematic biopsies•  200 standard 12-core biopsies to detect one extra

significant cancer•  17 low risk cancers detected for each high grade

Panebianco 2014 Urol OncolSiddiqui 2015 JAMAValerio 2015 Eur Urol

18

mpMRI, targeted & mapping biopsies identifymen likely to fail AS when selected byTRUS bx

19

Treatment Options are Broad & Unclear

?

20

21

Brachytherapy - radioactive seeds

22

23

There is a prboblem…

24

Do all cancers need the same treatment?

25

26

27

When confident cancer confined to one, treatingthat part may be enough - i.e. focal treatment

Prostate cancer on right side

Half the prostatescheduled for treatment∴ fewer side-effects

28

3D Models of the Prostate showlocation of cancer & treatment effect

29

Treatment Effect of HIFU

Cancer shown Cancer + MARGIN treated

30

31

Current treatments for BPH improveLUTS but cause sexual dysfunction

Surgery:HOLEP

Drugs:𝝰 blocker

32

Most men want urinary symptom relief& normal sexual function

33

UroLift relieves symptomsAND

preserves sexual function

34

Normal ejaculation requiresan intact bladder neck

35

Bladder neck dysfunctiongives retrograde ejaculation

36

UroLifts implant designed tocompress prostate lobes

Implant

Delivery device

37

UroLift retract prostate lobeswithout affecting bladder neck

38

UroLifts relieve urinary symptoms (IPSS)for at least 3 years with no attrition

IPSS

Que

stio

nnai

re P

oint

s

1 year 2 years 3 years

Storagesymptoms

Voiding symptoms

Roehrborn 2015 Can J Urol

39

Faster quality of life recoveryafter UroLift compared to TURP

Sonksen 2015 Eur Urol

UroLiftTURP

40

Faster urinary flow ratesafter TURP than UroLift

41

Residual Urine decreased lessafter UroLift compared tp HoLEP

• UroLift 10 ml•  TURP 200 ml• HoLEP 230 ml

42

Antegrade wet ejaculation & bettersex after UroLift compared to TURP

Sonksen 2015 Eur Urol

UroLiftTURP

Ejac

ulat

ory

& Se

xual

Fun

ctio

n

43

Incontinence less after UroLift

•  UroLift 5%•  TURP 11%•  HoLEP 14%

44

Side effects are transient & well tolerated

45

Day case UroLift saves money

HOLEP £2,355

UroLift £2,405

Bipolar TURP £2,562

Monopolar TURP £2,691

46

NICE 2015: UroLift recommended

47

48

UroLift fits well into the existing pathway

UroLift

HoLEP